Evidence map›Paper›PMID 36883068›Full record

ArticleInternational journal of nanomedicine2023

In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery.

Laura Deruyver, Clément Rigaut, Alejandro Gomez-Perez, Pierre Lambert, Benoit Haut, Jonathan Goole

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  6. Characterization of Spray-Dried Powders Using a Coated Alberta Idealized Nasal Inlet.Journal of aerosol medicine and pulmonary drug delivery · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Laura DeruyverLaboratoire de Pharmacie Galénique et Biopharmacie, Faculté de pharmacie, Université libre de Bruxelles, Brussels, Belgium.ORCID 0000-0003-2382-6350
Clément RigautTransfers, Interfaces and Processes (TIPs), École Polytechnique de Bruxelles, Université libre de Bruxelles, Brussels, Belgium.ORCID 0000-0003-4999-8601
Alejandro Gomez-PerezNanoMegas SRPL, Brussels, 1050, Belgium.ORCID 0000-0001-7454-5861
Pierre LambertTransfers, Interfaces and Processes (TIPs), École Polytechnique de Bruxelles, Université libre de Bruxelles, Brussels, Belgium.
Benoit HautTransfers, Interfaces and Processes (TIPs), École Polytechnique de Bruxelles, Université libre de Bruxelles, Brussels, Belgium.
Jonathan GooleLaboratoire de Pharmacie Galénique et Biopharmacie, Faculté de pharmacie, Université libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This work aimed to develop chitosan-coated cubosomal nanoparticles intended for nose-to-brain delivery of paliperidone palmitate. They were compared with standard and cationic cubosomal nanoparticles. This comparison relies on numerous classical in vitro tests and powder deposition within a 3D-printed nasal cast. Methods: Cubosomal nanoparticles were prepared by a Bottom-up method followed by a spray drying process. We evaluated their particle size, polydispersity index, zeta-potential, encapsulation efficiency, drug loading, mucoaffinity properties and morphology. The RPMI 2650 cell line was used to assess the cytotoxicity and cellular permeation. An in vitro deposition test within a nasal cast completed these measurements. Results: The selected chitosan-coated cubosomal nanoparticles loaded with paliperidone palmitate had a size of 305.7 ± 22.54 nm, their polydispersity index was 0.166 ± 0.022 and their zeta potential was +42.4 ± 0.2 mV. This formulation had a drug loading of 70% and an encapsulation efficiency of 99.7 ± 0.1%. Its affinity with mucins was characterized by a ΔZP of 20.93 ± 0.31. Its apparent permeability coefficient thought the RPMI 2650 cell line was 3.00E-05 ± 0.24E-05 cm/s. After instillation in a 3D-printed nasal cast, the fraction of the injected powder deposited in the olfactory region reached 51.47 ± 9.30% in the right nostril and 41.20 ± 4.59% in the left nostril, respectively. Conclusion: The chitosan coated cubosomal formulation seems to be the most promising formulation for nose-to-brain delivery. Indeed, it has a high mucoaffinity and a significantly higher apparent permeability coefficient than the two other formulations. Finally, it reaches well the olfactory region.

Indexed as

ChitosanPaliperidone PalmitateBrainNosePowdersChitosanPaliperidone PalmitatePowderscharged nanoparticleschitosancubosomesnasal castnasal powder formulationnose-to-brain deliveryRPMI 2650 cell line

Identifiers

PMID36883068
PMCPMC9985876
OpenAlexW4322741241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.